

# Lesley Seymour

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1476153/lesley-seymour-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108  
papers

17,480  
citations

49  
h-index

111  
g-index

111  
ext. papers

19,662  
ext. citations

7.7  
avg, IF

5.59  
L-index

#	Paper	IF	Citations
108	Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.. <i>Oncologist</i> , <b>2022</b> , 27, e286-e293	5.7	0
107	Prognostic and predictive effect of gene copy number and mutation status in early stage non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 826-838	4.4	1
106	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2461-2465	12.9	2
105	A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1442-1447	4.3	
104	A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1137-1144	4.3	14
103	A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1077-1084	4.3	9
102	RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1102-1110	2.2	24
101	A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). <i>Oncologist</i> , <b>2019</b> , 24, 1439-1445	5.7	21
100	Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6052-6060	12.9	31
99	Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27540	3	3
98	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. <i>Oncotarget</i> , <b>2018</b> , 9, 8155-8164	3.3	8
97	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2995-3006	2.2	120
96	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2018</b> , 7, 416-427	4.4	6
95	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , <b>2017</b> , 18, e143-e152	21.7	1010
94	MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S392-S393	8.9	9
93	RECIST - learning from the past to build the future. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 187-192	19.4	53
92	The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1358-1365	1.9	23

91	A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, e41-e49	4.9	2
90	BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2460-2470	12.9	7
89	A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. <i>Oncotarget</i> , <b>2017</b> , 8, 69651-69662	3.3	20
88	Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1818-28	10.3	60
87	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 850-61	8.9	57
86	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1223-30	2.2	194
85	Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 312-23	8.9	39
84	ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. <i>Cancer Epidemiology</i> , <b>2016</b> , 41, 50-6	2.8	5
83	A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 450-7	4.3	27
82	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3439-46	2.2	160
81	Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, e189-201	4.9	5
80	Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5057-63	12.9	2
79	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1379-88	21.7	103
78	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2050-6	7.5	50
77	Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4210-7	12.9	41
76	NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 410-3	8.9	12
75	Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4176-85	12.9	9
74	A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193. <i>Blood</i> , <b>2014</b> , 124, 5670-5670	2.2	1

73	ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1101-10	59.2	284
72	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2173-81	2.2	214
71	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 779-86	4.3	40
70	Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 1097-104	4	15
69	A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 963-72	8.9	25
68	Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1653-60	8.9	89
67	A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7511-7511	2.2	5
66	Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. <i>Clinical Investigation</i> , <b>2011</b> , 1, 33-44		2
65	Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1950-4	8.9	62
64	Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 139-47	8.9	53
63	Need for global partnership in cancer care: perceptions of cancer care researchers attending the 2010 australia and Asia pacific clinical oncology research development workshop. <i>Journal of Oncology Practice</i> , <b>2011</b> , 7, 324-9	3.1	10
62	Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 29-34	2.2	279
61	Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 49-55	2.2	206
60	Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5247-56	2.2	46
59	An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1710-8	12.9	71
58	Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4417-24	2.2	350
57	The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1764-9	12.9	117
56	Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1737-44	12.9	9

55	A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 252-60	1.9	67
54	Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 298-306	9.7	58
53	Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 220-8	8.9	160
52	The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 640-8	8.9	12
51	Controversies in the design of phase II clinical trials. <i>Clinical Advances in Hematology and Oncology</i> , <b>2010</b> , 8, 95-7	0.6	
50	Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4268-73	2.2	29
49	Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 586-94	8.9	16
48	Alternate endpoints for screening phase II studies. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1873-82	12.9	68
47	Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 708-13	12.9	43
46	Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1481-6	12.9	36
45	Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. <i>Cancer</i> , <b>2009</b> , 115, 5516-25	6.4	54
44	Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 404-10	2.2	124
43	Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2009</b> , 15, 354-60	2.2	13
42	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , <b>2008</b> , 14, 822-7	50.5	835
41	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4268-75	2.2	600
40	Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 54-9	2.2	233
39	Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2350-7	2.2	186
38	Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1871-8	2.2	111

37	A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 590-8	8.9	44
36	Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2008</b> , 876, 277-82	3.2	19
35	A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. <i>Investigational New Drugs</i> , <b>2008</b> , 26, 249-55	4.3	69
34	A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). <i>Investigational New Drugs</i> , <b>2008</b> , 26, 265-72	4.3	48
33	Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4278-84	2.2	176
32	Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5240-7	2.2	244
31	Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2256-61	2.2	39
30	Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 994-9	12.9	120
29	Venous Thromboembolism and Non-Small Cell Lung Cancer: A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials.. <i>Blood</i> , <b>2007</b> , 110, 3995-3995	2.2	
28	Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. <i>Clinical Lung Cancer</i> , <b>2006</b> , 7, 389-94	4.9	140
27	Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3831-7	2.2	255
26	Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 837-46	8.9	31
25	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. <i>Lancet Oncology, The</i> , <b>2005</b> , 6, 669-77	21.7	177
24	Erlotinib in lung cancer - molecular and clinical predictors of outcome. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 133-44	59.2	1594
23	A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2005</b> , 23, 143-9	2.8	45
22	Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2589-97	59.2	1469
21	Erlotinib in previously treated non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 123-32	59.2	4590
20	Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). <i>Investigational New Drugs</i> , <b>2005</b> , 23, 51-6	4.3	



19	Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2005</b> , 56, 154-60	3.5	36
18	A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130. <i>Investigational New Drugs</i> , <b>2005</b> , 23, 445-53	4.3	6
17	Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , <b>2005</b> , 23, 455-65	4.3	4
16	A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , <b>2005</b> , 23, 165-70	4.3	54
15	Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2831-9	2.2	135
14	Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 5928-34	12.9	77
13	Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 269-76	2.2	53
12	Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. <i>Lancet Oncology</i> , <b>2003</b> , 4, 397-406	21.7	243
11	Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 3025-34	2.2	211
10	A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 2457-64	12.9	40
9	Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 4227-39	12.9	362
8	A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. <i>Gynecologic Oncology</i> , <b>2002</b> , 84, 327-31	4.9	25
7	Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2567-74	2.2	20
6	Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 4434-9	2.2	214
5	The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. <i>Current Pharmaceutical Design</i> , <b>2002</b> , 8, 2279-84	3.3	16
4	Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2002</b> , 7, 153-7	2.8	48
3	A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2001</b> , 47, 2-10	3.5	15
2	Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 2876-81	2.2	182

- 1 P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. *Breast Cancer Research and Treatment*, **1995**, 36, 61-9 4.4 23